Cryptobiotix
Provider of validated, laboratory-based ex vivo gastrointestinal simulation services that model digestion, colonic microbiome fermentation and host interactions to generate mechanistic, translational preclinical evidence. Offers high-throughput automated workflows, donor cohort biobanking, compositional and metabolomic analysis, and reporting designed to inform IP, regulatory dossiers and clinical development.
Industries
Nr. of Employees
small (1-50)
Cryptobiotix
Products
Ex vivo gastrointestinal simulation platform
A modular laboratory platform that simulates human gastrointestinal digestion, colonic fermentation and host interactions for predictive preclinical testing.
Ex vivo gastrointestinal simulation platform
A modular laboratory platform that simulates human gastrointestinal digestion, colonic fermentation and host interactions for predictive preclinical testing.
Services
Laboratory studies that simulate digestion and colonic fermentation in screening (high-throughput) or prism (detailed) modes to evaluate efficacy, dosing and synergies.
Integration of fermentation outputs with epithelial–immune co-culture assays to measure barrier integrity and inflammatory endpoints.
Sequencing and metabolomics workflows, including quantitative sequencing, targeted SCFA measurement and untargeted metabolomics to link composition to function.
Cohort selection and biobanking of donor microbiota to enable studies that capture inter-individual variability and relevant target populations.
Laboratory studies that simulate digestion and colonic fermentation in screening (high-throughput) or prism (detailed) modes to evaluate efficacy, dosing and synergies.
Integration of fermentation outputs with epithelial–immune co-culture assays to measure barrier integrity and inflammatory endpoints.
Sequencing and metabolomics workflows, including quantitative sequencing, targeted SCFA measurement and untargeted metabolomics to link composition to function.
Cohort selection and biobanking of donor microbiota to enable studies that capture inter-individual variability and relevant target populations.
Expertise Areas
- Preclinical gut microbiome modelling
- Translational prediction of clinical microbiome outcomes
- Ex vivo fermentation assay development
- Microbiome compositional and metabolomic analysis
Key Technologies
- Ex vivo gastrointestinal simulation (digestion + colonic fermentation)
- Host epithelial–immune co-culture assays
- High-throughput automated fermentation workflows
- Time-resolved (kinetic) fermentation sampling
News & Updates
Preclinical ex vivo study showing the platform predicted in vivo compositional shifts for inulin, resistant dextrin and an HMO (2'FL).
Ex vivo study combining N-acetylglucosamine and immunoglobulin with fermentation and epithelial–immune co-culture readouts showing improved barrier integrity and SCFA production.
Kinetic ex vivo and clinical study indicating microbial conversion of nicotinamide riboside and related precursors to nicotinic acid with associated metabolite changes.
Preclinical ex vivo study showing the platform predicted in vivo compositional shifts for inulin, resistant dextrin and an HMO (2'FL).
Ex vivo study combining N-acetylglucosamine and immunoglobulin with fermentation and epithelial–immune co-culture readouts showing improved barrier integrity and SCFA production.
Kinetic ex vivo and clinical study indicating microbial conversion of nicotinamide riboside and related precursors to nicotinic acid with associated metabolite changes.